new
lung
infiltr
outpati
lung
heartlung
transplant
transpl
infect
di
right
reserv
abstract
background
infect
reject
repres
major
complic
follow
lung
transplant
often
associ
pulmonari
infiltr
differenti
diagnosi
infiltr
depend
time
transplant
aim
studi
character
lung
transplant
recipi
ltr
present
new
pulmonari
infiltr
method
retrospect
analysi
ltr
heartlung
transplant
recipi
attend
outpati
followup
institut
septemb
octob
perform
patient
present
new
pulmonari
infiltr
chest
xray
underw
bronchoscopi
includ
result
total
patient
account
attend
bronchoscopi
perform
seventyeight
patient
exhibit
new
pulmonari
infiltr
proceed
bronchoscopi
infiltr
occur
median
interquartil
rang
iqr
month
transplant
fortyeight
patient
male
median
patient
age
iqr
year
subsequ
investig
reveal
pneumonia
underli
caus
patient
remain
patient
chronic
lung
allograft
dysfunct
clad
respons
acut
reject
toxic
pneumon
patient
overal
surviv
ltr
present
new
infiltr
compar
ltr
attend
outpati
depart
conclus
new
pulmonari
infiltr
occur
first
month
ltr
like
due
infect
prompt
diagnosi
treatment
earli
mortal
appear
unaffect
late
mortal
remain
attribut
clad
pulmonari
infect
common
solid
organ
transplant
sot
recipi
immunocompromis
state
diagnosi
lung
transplant
recipi
ltr
difficult
organ
reject
mimic
mani
symptom
sign
pulmonari
infect
togeth
infect
acut
reject
ar
repres
commonest
seriou
complic
lung
transplant
ltx
etiolog
pulmonari
infiltr
appear
depend
time
present
transplant
surgeri
infect
repres
major
caus
earli
postop
period
bacteri
fungal
infect
commonest
first
month
transplant
subsequ
month
viral
fungal
infect
prevail
caus
pulmonari
infiltr
includ
acut
cellular
reject
chronic
lung
allograft
dysfunct
abbrevi
ar
acut
reject
bal
bronchoalveolar
lavag
bo
bronchiol
obliteran
syndrom
cfu
colonyform
unit
clad
chronic
lung
allograft
dysfunct
cmv
cytomegaloviru
crp
creactiv
protein
forc
expiratori
volum
first
second
iqr
interquartil
rang
ishlt
intern
societi
heart
lung
transplant
ltr
lung
transplant
recipi
ltx
lung
transplant
sot
solid
organ
transplant
tbb
transbronchi
biopsi
clad
drug
toxic
ar
remain
common
ltx
estim
incid
first
postop
year
interstiti
infiltr
occasion
conjunct
pleural
effus
chest
xray
may
suggest
ar
confirm
howev
requir
fiberopt
bronchoscopi
transbronchi
biopsi
tbb
bronchoalveolar
lavag
bal
perform
exclud
concomit
infect
incid
ar
appear
greatest
first
month
declin
markedli
thereaft
clad
appear
histolog
bronchiol
obliteran
function
defin
bronchiol
obliteran
syndrom
bo
loss
expiratori
lung
volum
drugrel
pulmonari
toxic
known
complic
amiodaron
sirolimu
mitomycin
treatment
indic
ltr
drug
toxic
therefor
requir
consider
particularli
pulmonari
infiltr
develop
earli
drug
initi
chest
xray
although
repres
sensit
readili
avail
diagnost
tool
offer
littl
specif
identifi
underli
caus
bronchoscopi
repres
mainstay
diagnosi
sampl
lower
respiratori
tract
eg
bal
tbb
essenti
differenti
infecti
noninfecti
caus
pulmonari
infiltr
aim
studi
analyz
etiolog
new
lung
infiltr
chest
xray
ltr
subsequ
underw
bronchoscopi
patient
retrospect
analysi
perform
ltr
heartlung
transplant
recipi
attend
outpati
clinic
institut
septemb
octob
data
retriev
transplant
databas
well
review
outpati
chart
retrospect
observ
studi
perform
accord
ethic
guidelin
declar
helsinki
accord
principl
ethic
committe
hannov
medic
school
neither
ethic
approv
inform
consent
necessari
data
acquisit
retrospect
observ
within
clinic
ii
data
anonym
iii
studi
reli
measur
rescu
therapi
appli
part
routin
care
addit
person
data
encrypt
chest
xray
perform
patient
outpati
visit
patient
xray
demonstr
new
infiltr
subsequ
underw
bronchoscopi
within
h
includ
xray
independ
evalu
experienc
radiologist
routin
comparison
previou
radiograph
radiologist
rereview
film
new
pulmonari
infiltr
defin
nodular
alveolar
interstiti
chang
identifi
previou
film
comput
tomographi
scan
perform
infiltr
nonresolv
noninfecti
etiolog
suspect
patient
persist
recurr
infiltr
includ
first
occas
new
infiltr
patient
particip
schedul
surveil
program
addit
urgent
visit
new
symptom
occur
initi
outpati
attend
schedul
week
surgeri
thereaft
patient
return
averag
time
first
year
reduc
visit
second
year
visit
subsequ
year
standard
tripledrug
immunosuppress
consist
calcineurininhibitor
prednisolon
either
cellcycl
inhibitor
mammalian
target
rapamycin
inhibitor
use
patient
comprehens
antiinfect
prophylaxi
consist
cotrimoxazol
along
either
voriconazol
itraconazol
valganciclovir
within
first
month
patient
high
intermedi
risk
administ
along
chest
xray
pulmonari
function
test
capillari
blood
ga
analysi
routin
blood
test
perform
visit
clinic
examin
review
result
perform
experienc
physician
immedi
decis
regard
bronchoscopi
reach
spirometri
perform
accord
guidelin
provid
american
thorac
societi
european
respiratori
societi
bo
stage
perform
accord
intern
societi
heart
lung
transplant
ishlt
criteria
baselin
forc
expiratori
volum
first
second
calcul
mean
best
postop
measur
taken
least
week
apart
within
surveil
program
schedul
fiberopt
bronchoscopi
bal
tbb
perform
month
post
ltx
thereaft
schedul
bronchoscopi
bal
perform
annual
basi
addit
bronchoscopi
perform
respons
new
respiratori
symptom
unexplain
deterior
graft
function
new
radiolog
chang
purul
secret
present
directli
aspir
sent
microbiolog
assess
quantit
cultur
gram
stain
antigen
test
respiratori
virus
legionella
pneumococci
aspergillu
galactomannan
perform
sampl
acidfast
stain
cultur
use
pleural
effus
assess
thoracocentesi
ultrasound
comput
tomographi
control
possibl
pleural
fluid
sampl
underw
direct
microscopi
cultur
biochem
immunocytolog
examin
new
infiltr
retrospect
review
underli
caus
determin
result
blood
test
microbiolog
histopatholog
find
well
subsequ
respons
treatment
pneumonia
defin
presenc
new
pulmonari
infiltr
plu
follow
criteria
bodi
temperatur
leukocyt
count
cellsmm
purul
tracheobronchi
secret
microbiolog
confirm
defin
presenc
pathogen
microorgan
respect
sampl
follow
threshold
colonyform
unit
cfu
ml
bronchial
brush
cfuml
bal
andor
cfuml
sputum
tracheobronchi
aspir
organ
identif
antibiot
suscept
test
perform
use
standard
method
invas
fungal
infect
defin
accord
european
organ
research
treatment
cancer
criteria
communityacquir
respiratori
virus
consid
pathogen
detect
antigen
test
polymeras
chain
reaction
cytomegaloviru
cmv
consid
caus
case
viru
detect
bal
combin
histopatholog
confirm
choic
antiinfect
treatment
taken
recent
recommend
local
frequent
isol
pathogen
antimicrobi
sensit
pattern
institut
previou
microbiolog
result
avail
patient
followup
clinic
certain
bacteria
fungi
isol
respiratori
sampl
consid
pathogen
consid
caus
agent
staphylococcu
epidermidi
streptococcu
viridan
enterococcu
speci
candida
speci
definit
ar
made
tbb
grade
accord
ishlt
criteria
restor
graft
function
follow
steroid
puls
assum
repres
ar
case
biopsi
avail
standard
treatment
ar
consist
mgkg
methylprednisolon
administ
intraven
daili
day
follow
augment
oral
prednisolon
toxic
pneumon
result
caus
agent
discontinu
lead
resolut
recurr
origin
lung
diseas
malign
allograft
posttransplant
period
histolog
confirm
lung
biopsi
data
present
number
percentag
median
interquartil
rang
iqr
continu
variabl
compar
use
ttest
mannwhitney
utest
categor
variabl
compar
use
chisquar
test
fisher
exact
test
result
consid
signific
valu
p
multivari
analysi
carri
logist
regress
model
use
stepwis
forward
method
surviv
analysi
transplant
compar
use
kaplanmei
method
comparison
use
logrank
mantelcox
test
followup
period
year
fig
period
observ
total
patient
particip
outpati
visit
result
bronchoscopi
perform
seventyeight
patient
present
new
pulmonari
infiltr
subsequ
underw
fiberopt
bronchoscopi
data
relat
patient
demograph
display
tabl
median
time
new
pulmonari
infiltr
month
iqr
follow
transplant
recent
period
median
time
transplant
patient
without
infiltr
month
rang
commonest
underli
diagnosi
infiltr
group
cystic
fibrosi
fifti
percent
cystic
fibrosi
patient
colon
colon
immedi
postop
period
follow
result
previou
studi
group
factor
demonstr
statist
signific
differ
p
infiltr
noninfiltr
group
includ
puls
temperatur
new
hypoxemia
recent
loss
leukocyt
count
creactiv
protein
crp
previou
diagnosi
bo
type
immunosuppress
tabl
summari
differ
etiolog
lung
infiltr
repres
figur
infect
account
case
right
lower
lobe
frequent
involv
fig
thirti
patient
exhibit
parapneumon
pleural
effus
occur
right
hemithorax
resolut
infiltr
common
infecti
etiolog
patient
noninfecti
etiolog
persist
infiltr
six
patient
infiltr
group
repeat
infiltr
two
recipi
singlelung
transplant
demonstr
infiltr
transplant
lung
bronchoscopi
identifi
purul
secret
patient
white
viscou
secret
patient
secret
record
addit
patient
secret
evid
patient
report
xray
chang
bal
perform
patient
aspir
secret
protect
brush
specimen
patient
new
lung
infiltr
infecti
origin
bal
isol
achiev
aspir
protect
brush
specimen
tbb
perform
patient
thoracocentesi
patient
blood
cultur
biopsi
result
grade
cellular
reject
patient
minim
acut
cellular
reject
ax
patient
biopsi
find
record
regard
bgrade
patient
exhibit
patient
bx
studi
period
endoscop
nebul
mitomycin
part
treatment
algorithm
patient
bronchial
stenos
approxim
patient
clear
time
correl
day
notic
new
infiltr
topic
mitomycin
spray
infiltr
resolv
spontan
etiolog
exclud
patient
attribut
toxic
pneumon
patient
diagnos
pneumonia
patient
leukocyt
count
cellsmm
patient
cellsmm
microorgan
isol
repres
tabl
case
pneumocysti
jirovecii
record
initi
treatment
identifi
infiltr
consist
antibiot
system
steroid
antivir
therapi
puls
corticosteroid
commonli
use
patient
clinic
suspect
ar
typic
patient
treat
empir
antibiot
fail
improv
day
case
patient
final
diagnosi
ar
chart
review
made
prompt
timerel
respons
clear
chest
xray
clinic
improv
pulsedos
steroid
case
third
patient
thirtyeight
patient
requir
hospit
quinolon
commonli
use
antibiot
follow
carbapenem
acylaminopenicillinbeta
lactamas
inhibitor
cephalosporin
case
inhal
antibiot
given
twelv
patient
present
new
lung
infiltr
fulfil
criteria
respiratori
failur
partial
pressur
infiltr
group
n
total
cohort
n
pvalu
oxygen
mmhg
cladnaiv
patient
present
pulmonari
infiltr
develop
clad
subsequ
month
compar
patient
noninfiltr
group
statist
signific
differ
p
howev
overal
surviv
similar
group
patient
control
group
pulmonari
infiltr
surviv
subsequ
surviv
figur
demonstr
signific
favor
patient
without
infiltr
compar
infiltr
vs
vs
surviv
respect
p
fig
regard
outcom
base
underli
caus
patient
exhibit
pulmonari
infiltr
infect
margin
wors
surviv
vs
compar
noninfect
etiolog
subsequ
year
vs
vs
respect
differ
surviv
observ
achromobact
haemophilu
influenza
enterococcu
speci
proteu
mirabili
fungal
aspergillu
fumigatu
percentag
proport
clad
repres
princip
caus
death
patient
exhibit
new
pulmonari
infiltr
n
remain
caus
death
includ
sepsi
n
neoplasm
n
pulmonari
embol
n
two
patient
die
within
year
transplant
sepsi
patient
demonstr
pulmonari
infiltr
caus
infect
death
attribut
clad
caus
death
outpati
shown
tabl
two
patient
die
earli
year
present
sepsi
caus
attribut
late
mortal
clad
caus
death
patient
infecti
origin
patient
ar
patient
clad
patient
pulmonari
toxic
multivari
analysi
crp
mgl
prove
sole
statist
signific
independ
risk
factor
pneumonia
tabl
sensit
elev
crp
mgl
infecti
etiolog
wherea
specif
knowledg
first
studi
investig
incid
etiolog
pulmonari
infiltr
ltr
foremost
find
studi
infiltr
identifi
outpati
attende
infect
identifi
primari
caus
primari
pathogen
respons
pneumonia
bacteri
fungal
viral
noninfecti
origin
especi
clad
import
differenti
diagnosi
report
literatur
frequent
lobe
involv
infiltr
group
middl
lower
lobe
total
associ
pleural
effus
case
date
largest
studi
examin
postltx
pneumonia
publish
spanish
research
network
transplant
resitra
contrast
data
cohort
patient
focus
mainli
earli
postop
period
median
followup
day
median
time
diagnosi
day
post
transplant
nonetheless
identifi
similar
pathogen
profil
bacteri
predomin
pseudomona
aeruginosa
cmv
aspergillu
speci
prove
common
contrast
find
infiltr
bear
surviv
earli
postop
pneumonia
detriment
affect
surviv
vs
studi
result
corrobor
sever
previou
studi
identifi
bacteri
pneumonia
due
staphylococcu
speci
p
aeruginosa
foremost
posttransplant
infect
observ
aspergillu
fumigatu
previous
report
commonest
fungal
organ
retrospect
studi
joo
et
al
immunocompromis
patient
pneumonia
includ
among
sot
recipi
includ
heart
lung
transplant
exact
number
specifi
sot
recipi
main
pathogen
isol
bal
also
bacteria
cmv
reason
lower
rate
nonbacteri
infect
might
definit
cmv
invas
fungi
stricter
studi
fungal
prophylaxi
intens
studi
case
p
jirovecii
record
studi
reflect
effect
strict
prophylaxi
patient
aspergillu
infect
colon
invas
bacteri
colon
infect
respiratori
virus
increas
risk
graft
failur
may
impact
surviv
accord
previou
studi
symptomat
viral
infect
increas
risk
new
onset
clad
risk
develop
bo
especi
increas
paramyxoviru
infect
overal
longterm
surviv
significantli
lower
outpati
diagnos
new
lung
infiltr
compar
present
new
infiltr
colon
frequent
recipi
infiltr
colon
risk
factor
clad
patient
might
increas
risk
well
clad
import
differenti
diagnosi
pulmonari
infiltr
follow
ltx
restrict
allograft
syndrom
recent
recogn
phenotyp
defin
sato
et
al
clad
irrevers
declin
total
lung
capac
consid
accur
distinguish
restrict
physiolog
baselin
patient
restrict
allograft
syndrom
typic
demonstr
signific
imag
find
peripher
interstiti
lung
diseas
lung
infiltr
spectrum
noninfecti
caus
ltr
broad
pulmonari
infiltr
postop
chest
xray
common
lung
vascular
injuri
donor
reimplant
diseas
reperfus
edema
primari
graft
dysfunct
vascular
obstruct
adult
respiratori
distress
syndrom
infect
atelectasi
reject
pharmacolog
toxic
posttransplant
lymphoprolif
disord
congest
heart
failur
malign
among
other
remain
caus
explan
caus
earli
radiograph
infiltr
frequent
determin
use
standard
tool
clinic
assess
judici
use
bal
tbb
cultur
bal
fluid
use
detect
pneumonia
caus
bacteria
viru
fungi
fact
use
protect
bal
shown
effect
use
protect
brush
specimen
diagnosi
bacteri
pneumonia
immunocompromis
patient
bone
marrow
transplant
although
tbb
may
falseneg
rate
reject
remain
gold
standard
practic
term
diagnosi
ar
biopsi
sampl
perivascular
mononuclear
infiltr
remain
cornerston
ar
diagnosi
valid
absenc
infect
accord
histopatholog
definit
acut
cellular
reject
requir
exclus
acut
infect
follow
databas
tbb
perform
patient
patient
adequ
tissu
materi
includ
ishlt
criteria
count
diagnost
patient
respiratori
failur
exclud
might
result
lowerthanexpect
number
biopsi
nevertheless
accord
ishlt
criteria
also
note
infectionreject
often
occur
togeth
confus
histolog
infect
need
rigor
exclud
accur
reproduc
interpret
pulmonari
allograft
biopsi
certainli
problem
definit
limit
proport
true
reject
episod
accord
prospect
studi
stolz
et
al
heterogen
popul
immunocompromis
patient
neutrophilia
bal
fluid
increas
serum
level
crp
procalcitonin
significantli
associ
bacteri
infect
infiltr
document
case
present
significantli
often
patient
proven
possibl
bacteri
infect
compar
nonbacteri
condit
studi
statist
signific
differ
crp
procalcitonin
valu
also
found
infecti
noninfecti
etiolog
wherea
bal
neutrophilia
achiev
statist
signific
differ
may
possibl
result
noninfecti
bal
neutrophilia
often
observ
ltr
especi
clad
signific
predictor
infecti
origin
univari
analysi
crp
procalcitonin
wherea
factor
appear
multivari
analysi
independ
risk
factor
pneumonia
crp
owe
smaller
number
studi
subject
unabl
evalu
independ
predictor
major
limit
studi
retrospect
design
singlecent
analysi
defin
sampl
size
infiltr
group
small
make
robust
analysi
relat
question
difficult
develop
pulmonari
infiltr
frequent
lifethreaten
complic
immunocompromis
patient
requir
earli
diagnosi
specif
treatment
multicent
prospect
studi
need
determin
potenti
benefit
combin
diagnost
approach
outpati
term
improv
surveil
earli
diagnosi
treatment
primari
caus
infiltr
outpati
ltr
new
infiltr
rais
high
suspicion
infect
need
invas
workup
lower
respiratori
tract
sampl
includ
tbb
patient
infiltr
follow
close
monitor
sign
chronic
graft
dysfunct
